Protalix BioTherapeutics Files 2025 Proxy Statement
Ticker: PLX · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1006281
| Field | Detail |
|---|---|
| Company | Protalix Biotherapeutics, Inc. (PLX) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, equity-awards
Related Tickers: PLX
TL;DR
Protalix BioTherapeutics (PLX) filed its proxy statement detailing exec pay and equity awards for FY24.
AI Summary
Protalix BioTherapeutics, Inc. filed its DEF 14A on April 30, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and equity awards granted to its principal executive officers and other employees. Key information includes the valuation of equity awards granted and vested during the fiscal year.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation, which can influence investor decisions and company governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and is not indicative of immediate financial risk.
Key Numbers
- 20250430 — Filing Date (The date the DEF 14A was filed with the SEC.)
- 2024-12-31 — Fiscal Year End (The end date of the reporting period for which compensation is detailed.)
Key Players & Entities
- Protalix BioTherapeutics, Inc. (company) — Filer
- 0001006281 (company) — Central Index Key
- 201-696-9345 (dollar_amount) — Business Phone
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a proxy statement, is used to solicit shareholder votes and provide information on matters such as director elections, executive compensation, and other corporate actions.
Who are the principal executive officers of Protalix BioTherapeutics, Inc. as indicated by this filing?
The filing indicates that information regarding equity awards is provided for 'PeoMember' (Principal Executive Officers) and 'NonPeoNeoMember' (Non-Principal Executive Officers, New Employees), but specific names are not listed in the provided excerpt.
What types of equity awards are discussed in the filing?
The filing mentions 'EqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember', 'ValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember', and 'EqtyAwrdsInSummryCompstnTblForAplblYrMember', indicating discussions of granted, vested, and summarized equity awards.
What is the SIC code for Protalix BioTherapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Protalix BioTherapeutics, Inc. is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
When was Protalix BioTherapeutics, Inc. formerly known as Embassy Acquisition Corp?
The company was formerly known as Embassy Acquisition Corp. until a date of name change on 19960124.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding Protalix BioTherapeutics, Inc. (PLX).